MedTrace Logo

COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital

NCT05074043 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 433

Last updated 2021-10-12

No results posted yet for this study

Summary

We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19.

All patients with COVID-19 associated Mucormycosis (CAM) admitted to Assuit University Hospital between March 1, 2021, and July 30, 2021, were included in this study. The patient characteristics, the site of mucormycosis, the comorbidities, the steroids usage, and the outcome were analyzed in people with COVID-19.

Conditions

  • Mucormycosis

Interventions

COMBINATION_PRODUCT

antiviral, surgical

surgical debridment

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-06-30
Completion
2021-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05074043 on ClinicalTrials.gov